Last updated: May 9, 2024
Sponsor: Protherics Medicines Development Limited
Overall Status: Active - Recruiting
Phase
N/A
Condition
Kidney Failure
Renal Failure
Kidney Disease
Treatment
Glucarpidase
High-dose methotrexate
Clinical Study ID
NCT05899751
PR001-CLN-pro101
All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- A diagnosis of any cancer from January 1, 2001 to June 30, 2021.
- Receipt of high-dose methotrexate chemotherapy, defined as a dose of 500 mg/m2 of bodysurface area or higher.
- Medical records available for review.
- Any age; any cancer type.
Exclusion
Exclusion Criteria:
- None.
Study Design
Total Participants: 1000
Treatment Group(s): 2
Primary Treatment: Glucarpidase
Phase:
Study Start date:
April 01, 2022
Estimated Completion Date:
December 31, 2024
Connect with a study center
Assistance Publique Hôpitaux de Marseille (APHM), La Timone Hospital
Marseille, 13354
FranceActive - Recruiting
University of Milan-Bicocca
Monza, 20900
ItalyActive - Recruiting
Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (VHIR)
Barcelona, 08035
SpainActive - Recruiting
Fundación Privada Instituto de Investigación Oncológica de Vall d'Hebron (VHIO)
Barcelona, 08035
SpainActive - Recruiting
Hospital Universitario Reina Sofía
Córdoba, 14004
SpainActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.